The polo-like kinase 1 (PLK1) inhibitor NMS-P937 is 

effective in a new model of disseminated primary CD56+ acute monoblastic leukaemia by Casolaro, A. et al.
  
 
 
 
 
Casolaro, A. et al. (2013) The polo-like kinase 1 (PLK1) inhibitor NMS-
P937 is effective in a new model of disseminated primary CD56+ acute 
monoblastic leukaemia. PLoS ONE, 8 (3). e58424. ISSN 1932-6203 
 
 
Copyright © 2013 The Authors 
 
 
 
http://eprints.gla.ac.uk/80547/ 
 
 
 
 
Deposited on:  3 June 2013 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk 
The Polo-Like Kinase 1 (PLK1) Inhibitor NMS-P937 Is
Effective in a New Model of Disseminated Primary CD56+
Acute Monoblastic Leukaemia
Alessia Casolaro1., Josee Golay2., Clara Albanese1, Roberta Ceruti1, Veronica Patton1, Sabrina Cribioli1,
Alice Pezzoni3, Marco Losa4, Gemma Texido1, Ursula Giussani5, Francesco Marchesi6, Nadia Amboldi1,
Barbara Valsasina1, Silvia Bungaro7, Gianni Cazzaniga7, Alessandro Rambaldi2, Martino Introna2,
Enrico Pesenti1, Rachele Alzani1*
1Oncology, Nerviano Medical Sciences, Nerviano, Milano, Italy, 2 Laboratory of Cellular Therapy ‘‘G. Lanzani’’, USC Haematology, Ospedali Riuniti, Bergamo, Italy,
3Department of Oncology and Haematology, Istituto Clinico Humanitas, Rozzano, Milano, Italy, 4 Pathology, Fondazione Filarete, Milano, Italy, 5Department of Medical
Genetics, Ospedali Riuniti, Bergamo, Italy, 6 Pathology, Accelera S.r.l., Nerviano, Milano, Italy, 7 Tettamanti Research Center, Pediatric Clinic, University of Milano–Bicocca,
Monza, Italy
Abstract
CD56 is expressed in 15–20% of acute myeloid leukaemias (AML) and is associated with extramedullary diffusion, multidrug
resistance and poor prognosis. We describe the establishment and characterisation of a novel disseminated model of AML
(AML-NS8), generated by injection into mice of leukaemic blasts freshly isolated from a patient with an aggressive CD56+
monoblastic AML (M5a). The model reproduced typical manifestations of this leukaemia, including presence of
extramedullary masses and central nervous system involvement, and the original phenotype, karyotype and genotype of
leukaemic cells were retained in vivo. Recently Polo-Like Kinase 1 (PLK1) has emerged as a new candidate drug target in
AML. We therefore tested our PLK1 inhibitor NMS-P937 in this model either in the engraftment or in the established disease
settings. Both schedules showed good efficacy compared to standard therapies, with a significant increase in median
survival time (MST) expecially in the established disease setting (MST= 28, 36, 62 days for vehicle, cytarabine and NMS-P937,
respectively). Importantly, we could also demonstrate that NMS-P937 induced specific biomarker modulation in
extramedullary tissues. This new in vivo model of CD56+ AML that recapitulates the human tumour lends support for
the therapeutic use of PLK1 inhibitors in AML.
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Introduction
AML is a heterogeneous disease that accounts for about 30% of
all adult leukaemias. The heterogeneity of AML was first
evidenced by morphological and immunophenotypic analyses of
the neoplastic cells. More recently an extensive genetic heteroge-
neity has also been identified, with a wide range of genetic
alterations detected, such as chromosomal imbalances (42% of
patients), recurrent chromosomal translocation/inversions/dele-
tions involving different chromosomes (15%) and point mutations
of specific genes, including FLT3, CEBPA, NPM1, DNMT3, to cite
only the most frequent events [1–3]. Several of the genetic
alterations or phenotypic markers have a prognostic impact on
therapy and/or can be novel drug targets [4–7].
CD56 (NCAM) expression is one of the prognostic markers in
AML. It is heterogeneously expressed in different haematopoietic
neoplasms, including AML, lymphomas and myelomas [8]. CD56
expression has usually been associated with poor prognosis in
different contexts and with extramedullary presentation of AML,
in particular meningeal involvement [9–11].
Conventional treatment for AML patients is based on a
combination of anthracyclines and cytosine arabinoside (ara-C).
However the heterogeneity of AML leads to response rates varying
from 30% to 90%, evidencing the need for new treatment options,
especially for poor prognosis AML subtypes [1,12]. PLK1 is a
serine/threonine (ser/thr) kinase involved in cell cycle regulation
at the G2/M transition and it is a direct target of the oncogenic
kinase Aurora A [13]. It is overexpressed in a variety of malignant
solid tumours and the development of inhibitors targeting this
mitotic kinase has already reached clinical trials with encouraging,
even if preliminary, evidence of antitumour activity [14]. Recently,
PLK1 has started to be considered a possible therapeutic target
also in myeloid leukemias, since it is overexpressed in the majority
of AML cells and these cells respond to PLK1 inhibitors in vitro
and in vivo [15].
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New orthotopic xenograft models using leukaemic cells directly
derived from patients have been developed and are an important
tool for the preclinical evaluation of new drugs since they are likely
to better represent the human disease [16–22]. In this study, we
report the successful establishment and extensive characterisation
of a novel model of aggressive disseminated AML, generated by
injecting into mice primary CD56+ leukaemic cells (AML-NS8)
obtained from an AML-M5a patient bearing trisomy 8 and 6. The
tumour is aggressive in vivo in SCID mice, and in large part
recapitulates the human disease with both medullary and
extramedullary leukaemic infiltration. Furthermore the AML-
NS8 cells responded favourably to our Polo-Like Kinase 1 (PLK1)
inhibitor NMS-P937 compared to standard therapy, both in vitro
and in vivo. These data suggest that PLK1 is a promising drugable
target for AML therapy.
Materials and Methods
Patient and Cells
The adult patient AML-NS8 presented in hospital with a
hypercellular bone marrow (BM) infiltrated by .90% with
CD342, HLA-DR+, CD33+, CD56+, CD72, CD192, a-napthyl
acetate esterase (ANAE) positive monoblast like cells. Cytogenetic
analysis (Q-banding) of the BM showed presence of 2 AML clones,
respectively with trisomy 8 e double trisomy 8 and 6 (7 and 15
metaphases out of 22, respectively). PCR analysis of BM sample
showed negativity for AML1-ETO and CBFb/MYH11 rearrange-
ments, MLL partial tandem duplication, NPM1, CEBPA and
FLT3-ITD and TDK mutations. The peripheral blood count was
above 200000 wbc/ml. He was diagnosed with AML M5a
according to FAB classification. The patient was enrolled in the
NILG AML 01/00 clinical protocol ‘‘Risk-oriented therapeutic
strategy for adult acute myelogenous leukaemia’’ (Clinicaltrials.gov
nu NCT00400673). Leukapheresis was performed and a first dose
of cytarabine infused to reduce the tumour burden. He died few
weeks after appearance of first symptoms. Leukaemic cells were
obtained from the leukapheresis after written informed consent
and approval by the local institutional ethics committee (Comitato
di Bioetica, Ospedali Riuniti, Bergamo). Mononuclear cells were
isolated by Ficoll-Hypaque gradient centrifugation and aliquots
frozen in 10% dimethyl sulphoxide.
Drugs
NMS-P937 is a previously described PLK1 inhibitor [23].
Cytarabine (ara-C) was from Hospira (Lake Forest, IL, USA) and
doxorubicin from Bedford Laboratories (Bedford, OH, USA).
In vivo Expansion of AML-NS8 Cells
All procedures adopted for housing and handling of animals
were in strict compliance with European and Italian Guidelines for
Laboratory Animal Welfare. The protocol was approved by the
Ethics of Animal Experiments Committee of Nerviano Medical
Sciences. All efforts were made to minimize suffering. 50–1006106
thawed AML-NS8 cells were injected intraperitoneally (ip) into
irradiated NOD/SCID mice (Charles River Laboratories-Calco,
Italy), as previously described [17,18]. Animals were sacrificed
when ascitic fluid was observed and leukaemic cells were collected
from the abdominal cavity. Recovered AML-NS8 cells were
further expanded in groups of 5–10 SCID mice (Charles River
Laboratories) by serial ip passages using 10–206106cells/mouse.
After 5 in vivo passages, the phenotype and genotype of collected
and pooled cells were verified by flow cytometry, cytogenetic and
SNP arrays analysis. These cells were frozen in aliquots for further
studies.
Table 1. Phenotype of AML-NS8 cells, at diagnosis, expanded ip in mice or expanded in vitro with rh-IL3 and rh-GM-CSF.
Phenotype*
Antigen Antigen function Leukapheresis (diagnosis) In-vivo expanded cells In vitro cultured cells
CD3 TCR neg neg neg
CD7 T cell marker neg ND ND
CD19 Costimulatory, pan-B neg neg neg
CD34 HSC marker neg neg neg
CD13 alanine aminopeptidase ++ + ++
CD33P SIGLEC lectin ++ ++ ++
HLA-DR Histocompatibility ++ +++ ++
CD10 Metalloproteinase + + +
CD123 IL3R + ND +
CD25 P IL2R neg neg neg
CD117 SCF-R,c-kit neg neg neg
CD11b heterodimer: MAC1, CR3 +++ ++ ++
CD18 heterodimer: MAC1, CR3 +++ ++ ++
CD11c CR4 ++ ND +
CD52 GPI-linked,alemtuzumab target +++ ++ ++
CD56 NCAM ++ ++ +
ANAE** a-napthyl acetate esterase +++ +++ +++
*Neg: ,10% staining; +: ,80% staining or MFI,100; ++: 80–100% staining and MFI 100–400; +++: 80–100% staining and MFI.401 by flow cytometry. ND: not done.
Immunophenotypes were performed three times.
**Cytochemical staining for fluoride sensitive ANAE.
doi:10.1371/journal.pone.0058424.t001
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Disseminated Primary Leukaemia Model and Treatment
Protocol
Unless otherwise indicated 56106 pooled in vivo expanded
AML-NS8 cells (from 5th passage) were transplanted into 5 weeks
old SCID mice by tail-vein injection (iv). Animals were monitored
for the insurgence of leukaemic signs, sacrificed when moribund
and autopsied. For histopathology column, femour, sternum,
whole skull, spleen, stomach, gut, liver, kidney, skin and lung
tissues were collected. For flow cytometry, blood was taken by
retro-orbital bleeds, BM was obtained by flushing it from femurs
with PBS and spleen was mechanically dissected.
For in vivo experiments, in the engraftment setting (preemptive
protocol) treatments started on day 4 after AML-NS8 iv injection.
Mice were randomly assigned to one of the following groups:
vehicle ip, cytarabine (75 mg/kg ip per day over 5 days for 4 cycles
with 7 day rest), doxorubicin (3 mg/kg iv every 7 days for 3 cycles)
or NMS-P937 (120 mg/kg os per day over 2 days for 4 cycles with
a 10 day rest). Furthermore, in the established disease setting
(therapeutic protocol), treatments started on day 20 after AML-
NS8 injection when leukaemic dissemination was evaluable and
mice were randomly divided into the following groups: vehicle ip,
cytarabine (75 mg/kg ip per day over 5 days with 5 day rest,
continued until mice were moribund), or NMS-P937 (60 mg/kg
bid os per day over 2 days with a 5 day rest, continued until mice
were moribund). Animals were monitored for clinical signs of
disease and time of death recorded. All animals were autopsied.
Histology and Immunohistochemistry
Organs collected were fixed in 10% buffered formalin for 24
hours and 5% formic acid was added to decalcify bone structures.
Tissues were prepared, stained with haematoxylin and eosin
(H&E) and processed for immunohistochemistry as previously
described [14,24]. Briefly, slides were heat unmasked using low
(Vector Laboratories, Burlingame, CA, USA) or high (Dako,
Glostrup, Denmark) pH solutions and incubated with primary
antibodies anti-human HLA,A,B,C (MBL, Woburn, MA, USA),
anti-human phospho-H3 (Upstate, Charlottesville, VA,USA),
phospho-NPM1 phospho-TCTP (Cell Signaling, Danvers, MA,
USA) and active Caspase 3 (Cell Signaling, Danvers, MA, USA).
Envision+ System HRP anti-mouse and rabbit (Dako, Glostrup,
Denmark) were used as secondary antibodies.
In vitro Expansion
Pooled in vivo expanded AML-NS8 cells from passage 5 were
cultured at 0.5–16106/ml in RPMI-1640 medium (Invitrogen,
Carlsbad, CA, USA), supplemented with 20% foetal calf serum
(Euroclone, Wetherby, West Yorkshire,UK), 1 ng/ml recombi-
nant human granulocyte-macrophage colony-stimulating factor
(rhGM-CSF) and 10 ng/ml interleukin-3 (rhIL-3)(both from
Sigma-Aldrich, Gillingham, UK). To calculate doubling time,
cells were seeded at 506103cells/ml in duplicates in complete
medium and counted daily in a Coulter Counter (Coulter, Brea,
CA, USA) for 8 days.
In vitro Assays
AML-NS8 cells (2000 cells/well) were seeded in 384 well-plates
in complete medium and incubated at 37uC and 5% CO2. After
24 hours increasing concentrations of doxorubicin (range 1 mM -
0,004 mM), cytarabine or NMS-P937 (range 10 mM - 0,001 mM)
were added and incubation continued for further 72 hours. Cells
were then processed by CellTiter-Glo assay (Promega, Madison,
WI, USA) following the manufacturer’s instructions. Inhibitory
activity was evaluated using the Symyx Assay Explorer (Symyx
Technologies Inc., Santa Clara, CA, USA) program. The
concentration resulting in 50% inhibition (IC50) was calculated
using the sigmoidal interpolation curve.
For in vitro mechanism of action studies, AML-NS8 cells were
seeded at 1.56106/ml and treated with 0.2 mM NMS-P937 for 24
hours or 0.75 ng/ml Nocodazole for 16 hours. One part of cells
were then lysed for western blotting and the other fixed in ethanol
Figure 1. In vitro and in vivo growth of AML-NS8 cells. (A) Neoplastic cells were plated in vitro at 506103 cells/ml in presence of rhIL-3 and
rhGM-CSF. Cells were counted at the indicated times to determine the doubling time (DT= 31hours). The data are representative of 3 experiments.
(B) On day 0, groups of 10 SCID mice were inoculated iv with either 16106 (dotted line) or 56106 (continuous line) in vivo expanded AML-NS8 cells
and survival time recorded. The median survival time (MST) was 37 and 28 days respectively.
doi:10.1371/journal.pone.0058424.g001
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70% and stained with Alexafluor 488 conjugated anti-phospho-
Histone H3 antibody (Cell Signaling, Danvers, MA, USA) and
propidium iodide (Sigma Aldrich, Gillingham, UK) for FACS
analysis.
Flow Cytometry
For standard immunophenotyping, cells in suspension were
stained with CD3-PE, CD19-FITC, CD33-PE, HLA-DR-PE,
CD10-FITC, CD123-PE, CD25-PE, CD11b-PE, CD18-FITC,
CD56-PE (all from BD Biosciences, Franklin Lakes, NJ, USA),
CD52-PE (Caltag Laboratories, Burlingame, CA), CD117-PE
(Immunotech, Mississauga, ON, Canada), and analysed by
FACSCalibur (BD Biosciences, Franklin Lakes, NJ, USA).
Western Blotting
Cells extracts and immunoblotting were performed as previ-
ously described [14] and staining was done using the following
primary antibodies against: PLK1 (Zymed, San Francisco, CA,
USA), NPM1 and pThr199 NPM1 (both from Cell Signaling,
Danvers, MA, USA), Histone H3 (Abcam, Cambridge, UK),
pSer10 Histone H3 (Upstate, Charlottesville, VA,USA). Second-
ary anti-mouse-HRP or anti-rabbit-HRP conjugates were from
Thermo Scientific (Waltham, MA, USA) and ECL detection
reagent from Amersham (GE Healthcare Ltd, Amersham, UK).
Single Nucleotide Polymorphisms (SNP) Arrays Analysis
Diagnostic, in vivo (passage 5) and in vitro expanded AML-NS8
cells (passage 15) were genotyped using AffymetrixH Cytogenetics
Whole Genome 2.7 M Array (AffymetrixH, Santa Clara, CA,
USA), as previously described [25].
Results
In vivo and in vitro Expansion of AML-NS8 Cells
Since expression of CD56 (NCAM) has been observed in a
significant proportion of cases of AML, ALL, MM and B-NHL
and is associated with extramedullary involvement and poor
prognosis, we have selected one case of aggressive CD56+ AML
for in vivo inoculation in mice. In this study AML-NS8 cells were
directly derived from a patient with an aggressive CD56+ AML
(whose characteristics are described in Materials and Methods)
and were injected intraperitoneally (ip) into NOD/SCID mice.
These cells engrafted well and expanded within the abdominal
cavity, leading after a few weeks to the production of both ascites
and solid tumour masses in this body location. Repeated passages
of cells ip into SCID mice allowed their expansion to generate a
large pool of leukaemic cells. Their phenotype was analyzed using
a panel of 16 antibodies directed against cell lineage markers and
cytokine receptors and it was identical to that of the blasts at
diagnosis, including lack of expression of CD34, CD117, CD25,
CD3, CD7 and CD19 and clear expression of the myeloid markers
CD13, CD33, CD11b, CD11c, CD18, HLA-DR, CD10, CD123
(IL-3R), CD52 and notably of CD56 (NCAM). Furthermore, the
Figure 2. Histological and immunohistochemical analysis of different tissues. SCID mice were inoculated iv with 56106 AML-NS8 cells,
monitored for clinical signs and sacrificed upon manifestations of terminal disease. Different tissues were collected and fixed for histology and
immunohistochemistry. (A) Clinical signs and histopathological characterisation of AML-NS8 in vivo disseminated model. (B, C) Representative
pictures (Axio Scope Zeiss, magnification6200) of the indicated tissues stained with H&E (left panels) or anti-human HLA-A,B,C (right panels). Black/
white bar, 100 mm.
doi:10.1371/journal.pone.0058424.g002
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expanded cells stained positive for fluoride sensitive ANAE by
cytochemical staining, like the diagnostic sample (Table 1).
In order to establish also an in vitro growing cell line for
preliminary drug testing and mechanistic studies, AML-NS8 cells
were put in culture in the presence of growth factors. In these
conditions cells were able to expand in vitro, with a doubling time
of 31 hours (Figure 1A) and could be cultured for at least 3
months, preserving their phenotypical identity with sample at
diagnosis (Table 1).
The karyotype of the in vivo and in vitro expanded cells was also
compared to that of the leukapheresis and BM samples, both taken
at diagnosis. By standard Q-banding, the leukapheresis sample
showed the double trisomy of chromosomes 6 and 8 and this was
observed in 28 out of 31 metaphases. The other 3 metaphases
were apparently normal, suggesting that they represented
contaminating normal cells present in peripheral blood (Table 2).
These data suggest that in the periphery, only the clone with
double trisomy was present, in contrast to BM, where an
additional clone with only trisomy 8 was also detected and
represented about 32% of analysed metaphases (Table 2 and
Figure S1A). The double trisomy 6/8 was shown in all 28
metaphases from pooled in vivo expanded cells at passage 5, as
expected since they derived from the leukapheresis sample (Table 2
and Figure S1B) and this data was also confirmed by FISH using
chromosome 6 and 8 probes (Figure S1C). The in vitro expanded
cells, as expected, showed in all metaphases the double chromo-
some 6/8 trisomy, but also a small deletion on the short arm of
chromosome 10 difficult to clearly identify (Table 2). No other
cytogenetic abnormalities [NPM1, CEBPA and FLT3 (ITD and
TKD) mutations, MLL partial tandem duplication, AML1/ETO
and CBFb/MYH11 translocations] were detected in the diagnostic,
in vivo and in vitro expanded cells by PCR analysis (data not
shown).
Figure 3. PLK1 expression in AML-NS8 cells and activity of PLK1 inhibitor NMS-937 in vitro and in vivo. (A) Western blot analysis.
Leukaemic cells at diagnosis, expanded in vivo or in vitro and PBMCs from healthy volunteers were lysed and PLK1 expression analysed by Western
blot. GAPDH protein expression was used as loading control. (B) Cytotoxicity assay. AML-NS8 in vitro expanded cells were incubated in presence or
absence of increasing concentrations of cytarabine, doxorubicin and NMS-P937 for 72 hours and IC50 determined for each drug. (C) In vivo efficacy:
preemptive protocol. Groups of 10 mice were inoculated iv with 56106 AML-NS8 cells and treated with vehicle, cytarabine at 75 mg/kg ip per day
over 5 days for 4 cycles with a 7 day rest, doxorubicin at 3 mg/kg iv every 7 days for 3 cycles and NMS-P937 per os at 120 mg/kg per day over 2 days,
for 4 cycles with a 10 day rest and survival recorded. The Kaplan-Meier plot and MST are shown. Statistical analysis using the Wilcoxon test showed
that all drug treatments were statistically different from vehicle alone (p,0.01 for cytarabine and p,0.001 for NMS-P937 and doxorubicin). NMS-P937
was also statistically different from the other drugs with p,0.05. Data are representative of 2 independent experiments. (D) In vivo efficacy:
therapeutic protocol. Groups of 10 mice were inoculated iv with 56106 AML-NS8 cells and treatments started at day 20, when a clear leukaemic
dissemination was visible. Mice were treated with vehicle, cytarabine at 75 mg/kg ip per day over 5 days with a 5 day rest continuously until mice
were moribund, and NMS-P937 per os at 60 mg/kg bid per day over 2 days with 5 day rest continuously until mice were moribund and survival
recorded. The Kaplan-Meier plot and median survival times (MST) are shown. Statistical analysis using the Wilcoxon test showed that all drug
treatments were statistically different from vehicle alone (p,0.0001 for each compound). NMS-P937 was also statistically different from cytarabine
with p = 0.001.
doi:10.1371/journal.pone.0058424.g003
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In order to assess in more details the genetic stability of AML-
NS8 cells, whole genome SNP arrays analysis was performed on
genomic DNA from the leukapheresis sample obtained at
diagnosis, as well as from the in vivo and in vitro expanded cells.
The genomic copy number (CN) profile obtained by SNP arrays
on the diagnostic sample showed a number of deletions on
chromosome loci 3q26, 9p21, 10p12, 11p14, 11q23 and 17p13, as
well as a gain at the 14q21 locus, as detailed in Table 2. These
deletions were too small to be detected by standard Q-banding.
Parallel analysis of the genomic profiles of the in vivo expanded
cells revealed that they were genetically stable with respect to the
diagnostic leukapheresis sample, since they showed identical
number and sizes of deletions and gains of genetic material
(Table 2). In contrast, in vitro expansion of the cells induced the
appearance of one ex novo genetic alteration on chromosome 11
and two larger deletions with respect to the leukapheresis sample,
but at similar chromosomal positions (Table 2). The larger loss on
chromosome 10p was also detected by Q-banding (Table 2). The
considerable gain on chromosome 13 and the larger deletion on
chromosome 11q23.3 were confirmed by FISH analysis using
probes specific for these chromosomes (LAMP1, D13S319 and
ATM, respectively). Thus FISH revealed that the gain of the long
arm of chromosome 13 was joined to the deleted long arm of
chromosome 11, such that this anomaly was not readily detectable
by standard Q-banding (data not shown). Other anomalies, as for
the diagnostic clone, were too small to be visible by Q-banding.
It is worth noting that all losses detected by SNP arrays were
monoallelic, except that at locus 9p21 which was biallelic. This loss
included a 116 kbp region that contained the tumour suppressor
gene CDKN2A (p16INK4A) and MTAP (methylthioadenosine
phosphorylase). This biallelic loss was present on all samples
(Table 2).
These data demonstrate that in vitro growth of leukaemic cells
induces genetic alterations which are not initially present or
detectable at diagnosis. In contrast in vivo expansion of the cells
preserves a more stable genotype.
Characterisation of a Disseminated Model of AML-NS8
Leukaemia
In order to generate a model of disseminated leukaemia, AML-
NS8 cells obtained from intraperitoneal passage 5 were inoculated
by iv route in SCID mice. Two different AML-NS8 cell
concentrations (16106 and 56106/mouse) were tested. As shown
in Figure 1B, these two injections led to a median survival time
(MST) of 37 and 28 days, respectively. Injection of 56106 cells was
chosen for further experiments of disseminated leukaemia, since
this schedule gave a reproducible MST of 29 days 61 (calculated
on 8 independent experiments).
With the view to perform a complete analysis of the organs
involved and of the localisation of tumour cells in the AML-NS8
disseminated model, 40 mice coming from 4 different experiments
were monitored and euthanised when they showed manifestations
of terminal disease. Clinical signs observed included hind limb
paralysis in 75% of animals, presence of visible masses on the body
surface in 23% of the cases (Figure 2A) and respiratory failure in
the majority of the animals. At autopsy macroscopic analysis
revealed that masses were always localised on the surface of bones,
mainly of limbs, column and skull.
As shown in Figure 2A, the histopathological evaluation of
collected organs showed the presence of neoplastic cells in 100% of
marrow samples in femur, column or skull bones. In other
haematopoietic organs, such as spleen and the few evaluable
lymph nodes (data not shown), no neoplastic infiltration was
detected by H&E. Several non haematological organs were also
affected, since 100% of animals had neoplastic cells in the lungs
and about 90% in meninges and soft tissues. In contrast only 13–
20% of cases analysed had the kidney and liver infiltrated, while in
stomach, gut, skin, brain and spinal cord neoplastic cells were
never observed. Finally, invasion within the periodontal space of
mandibular or maxillary bones was also detected.
In the organs where histopathology did not clearly allow to
detect leukaemic infiltration, immunohistochemistry staining for
human HLA-A,B,C showed the variable extent of infiltration of
Figure 4. Leukaemic infiltration of meninges and soft tissues from mice treated with NMS-P937 and cytarabine following a
therapeutic schedule. Mice were inoculated iv with 56106 AML-NS8 cells and treatments started at day 20, when leukaemic dissemination was
present. Mice were treated with vehicle, NMS-P937 per os at 60 mg/kg bid per day over 2 days with 5 day rest and cytarabine at 75 mg/kg ip per day
over 5 days with a 5 day rest, continuously until mice were moribund. Organs were collected for histological and immunohistochemical analysis. The
graphs show the qualitative evaluation of leukaemic infiltration (expressed as score) in meninges (A) and soft tissues (B). Score: 0 = no infiltration,
1 =minimal, 2 =moderate, 3 =marked, 4 = severe infiltration.
doi:10.1371/journal.pone.0058424.g004
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the different femoral bone marrow samples as well as the presence
of only scattered neoplastic cells, single or in small groups, in
spleen (Figure 2B) and also in lung, liver and kidney (Figure 2C).
Flow cytometry results, performed on cellular suspensions stained
with the same antibody, confirmed the variable infiltration in the
femoral marrow (1–94%; median 24%), the low dissemination in
the spleen (0–4%; median 1%) and showed neoplastic cells in all
blood samples analysed (1–29%, median 6%).
The detailed analysis of macroscopic masses, exclusively
composed of tumour cells as histopathologically revealed, showed
that they infiltrated muscles and always were associated/adjacent
to bone periosteum. The marrow contained in these bones was
often replaced completely by tumoural cells and bone remodeling/
resorption processes were evident (Figure S2A). Similarly in the
skull, infiltration of the meninges was a prominent finding (Figure
S2B), confirmed by preliminary data obtained by magnetic
resonance imaging (MRI, Figure S2C).
We conclude that the disseminated AML-NS8 model recapit-
ulates several clinical characteristics of extramedullary AML, with
the involvement of both haematopoietic and non-haematopoietic
organs, most prominently meninges, muscle and lung as well as the
masses appearance.
In vitro and in vivo Activity of PLK1 Inhibitor NMS-P937
on AML-NS8 Cells in Comparison with Standard Drugs
The conventional induction and consolidation therapy for AML
is a combination of cytarabine and anthracycline, but new drugs
are required for aggressive and resistant forms of the disease.
PLK1 has been demonstrated to be overexpressed in several AML
patient samples and is a candidate target protein for therapy
[15,26,27]. We therefore evaluated PLK1 expression in the
diagnostic, in vivo and in vitro expanded AML-NS8 cells by
Western blot analysis. As shown in Figure 3A, PLK1 was
expressed in all samples, but not in normal peripheral blood
mononuclear cells (PBMC).
Given the expression of PLK1 by AML-NS8 cells, we used these
cells in vitro as target for the cytotoxic activity of our proprietary
PLK1 inhibitor NMS-P937 [14,23], in comparison with cytara-
bine and doxorubicin. The in vitro efficacy of the compounds,
expressed as IC50 calculated after 72 h treatment, was 133 nM,
23 nM and 36 nM for cytarabine, doxorubicin and NMS-P937,
respectively (Figure 3B). These data suggested an overall
favourable activity of the PLK1 inhibitor in vitro against AML-
NS8 cells.
Figure 5. Mechanism of action of PLK1 inhibitor in vitro and in vivo. In vitro experiments: AML-NS8 cells were untreated (CTRL) or treated
with 0.2 mM NMS-P937 for 24 hours or 0.75 ng/ml nocodazole for 16 hours. (A) biparametric analysis for phospho-Histone H3 and DNA content by
flow cytometry. Inserts show the correspondent cell cycle profile and indicate the percentage of cells in G2/M phase. (B) Western blot analysis of total
cell lysates for the following proteins: phospho-NPM1 (pNPM1), NPM1, phospho-Histone H3 (pH3), Histone H3 (H3). Tubulin protein expression was
used as loading control. In vivo experiments: (C) Solid tumour masses from vehicle or NMS-P937 treated animals were collected, fixed and stained
with H&E or antibodies against phospho-TCTP (pTCTP), phospho-Histone H3 (pH3), phospho-NPM1 (pNPM1) or active Caspase 3. Representative
pictures are reported (Axio Scope Zeiss, magnification6400). Black/white bar, 50 mm.
doi:10.1371/journal.pone.0058424.g005
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The same drugs were then tested in vivo in the AML-NS8
disseminated model following a preemptive protocol as described
in Materials and Methods. All compounds had activity compared
to vehicle (MST of 29, 40, 42 and 51 days for vehicle, doxorubicin,
cytarabine, and NMS-P937, respectively) (Figure 3C). Important-
ly, PLK1 inhibitor treatment produced a significant (p,0.05)
increase of MST (51 days) compared to standard therapies (40–42
days) (Figure 3C). Similar results were obtained in 2 independent
experiments.
On the basis of the significant effect of NMS-P937 in the
preemptive protocol, we investigated the efficacy of the compound
in an established AML-NS8 disease in comparison with cytara-
bine. In this experiment, treatments (as specified in Materials and
Methods) started at day 20 after tumoural cells injection, since in
previous time course experiments a clear dissemination was
evaluable from the third week post engraftment (data not shown).
As shown in Fig 3D both compounds significantly prolonged
survival compared to vehicle (MST=28, 36, 62 days for vehicle,
cytarabine and NMS-P937 respectively) also in the established
disease setting. Also in this case, our PLK 1 inhibitor was
statistically different from cytarabine with p= 0.001.
Importantly, while % T/C (1006MST treated group/MST
vehicle group) of cytarabine is comparable in the two different
schedules (146% and 128% in the engraftment and established
disease setting, respectively), NMS-P937 showed a better %T/C in
the established disease (221% versus 175% in the engraftment
setting). Histological analysis indicated that the PLK1 inhibitor
significantly decreased (in 5 out of 7 cases) or abolished (in 2 out of
7 cases) leukaemic infiltration in the meninges and soft tissues
compared to cytarabine or vehicle in a therapeutic protocol. These
data were confirmed by anti-human HLA A,B,C immunohisto-
chemical staining of the tissues (Figure 4).
In vitro and in vivo Mechanism of Action of PLK1 Inhibitor
NMS-P937 on AML-NS8 Cells
PLK1 inhibitors have been shown to induce NPM1 and Histone
H3 phosphorylation which are hallmarks of the mitotic block
induced by the drug. Furthermore NMS-P937 inhibits phosphor-
ylation of translational controlled tumour protein (TCTP), a direct
target of PLK1 in solid tumours [28]. We therefore investigated
the mechanism of action of NMS-P937 in AML-NS8 cells in vitro.
As shown in Figure 5A, a 24 hour treatment induced an
accumulation of cells in G2/M (60% vs 7% in control cells),
similarly to what observed with the classical anti-mitotic drug
Nocodazole (52%), to which corresponded a strong increase of
phospho-Histone-H3 expression (1.4%, 35% and 32% in control,
NMS-P937 and Nocodazole respectively). Western blot analysis of
the same samples confirmed the modulation of phospho-Histone-
H3 in vitro and revealed also the increased level of phospho-NPM1
expression compared to untreated cells (Figure 5B). We next
studied the specific inhibition of PLK1 by NMS-P937 also in vivo,
verifying if the compound was able to reach the extramedullary
infiltrates. Vehicle and treated animals were monitored and when
they showed manifestations of terminal disease they were given a
boost of vehicle or NMS-P937 at 120 mg/kg and 6 hours later, at
sacrifice, tumour masses and organs were collected. A clear
modulation of PLK1 specific biomarkers was visible by immuno-
histochemistry. Indeed a complete inhibition of phospho-TCTP
expression and induction of phospho-Histone H3 and phospho-
NPM1 could be observed in skull and column masses from NMS-
P937 treated animals (Figure 5C) and interestingly also in nearby
meninges (Figure S3). These data demonstrate that our PLK1
inhibitor is able to modulate phosphorylation of specific substrates
in extramedullary tumour infiltrates. Therefore, immunohisto-
chemical staining for Caspase 3 activation revealed as NMS-P937
induces apoptosis as already reported for solid tumours [14]
(Fig 5C).
Discussion
Acute myeloid leukaemia is a heterogeneous disease, classifiable
in different subtypes, which presents with highly variable and
sometimes multiple cytogenetic, molecular and phenotypic
abnormalities. Some of these aberrations correlate with response
to therapy and survival. Despite significant progress in the
treatment of AML, relapse and resistance are still common,
calling for more effective therapies, whose development would
require animal models recapitulating the patho-physiological
features of these different disease entities [16–19,22,27]. In this
report, we characterise in detail a new in vivo model of a primary
disseminated AML, named AML-NS8, derived from the leuka-
pheresis sample of a patient with a very aggressive CD56+ acute
monoblastic leukaemia (M5a). In mice the cells engrafted well and
expanded within the abdominal cavity with the production of both
ascites and solid tumour masses. Expanded cells were very similar
to the primary tumour in terms of morphology, immunopheno-
type and karyotype. Indeed Q-banding revealed that all leukaemic
cells at the 5th passage ip carried the double trisomy 8 and 6
already present in the leukapheresis sample at diagnosis. Besides,
no other cytogenetic abnormalities or mutations were detected and
the more refined genotype study by copy number analysis in SNP
arrays demonstrated their genomic stability. In contrast, the same
cells expanded in vitro for 5–6 weeks showed several additional
chromosomal focal deletions and gains. These data support the
view that, whereas the in vitro establishment of cell lines induces
multiple genetic alterations that accumulate with time, in vivo
expansion does not generally do so with such high frequency
[17,18,20]. Thus the apparent identity of phenotype, genotype
and general behaviour of the leukaemic cells at diagnosis and after
in vivo passages suggests that these cells can indeed provide a
predictive and reliable animal model of an aggressive AML.
Interestingly a biallelic loss of the p16INK4 gene was detected
already at diagnosis in AML-NS8 cells. Biallelic mutations or
deletions of this tumour suppressor gene is a common event in
cancer [29] including leukemia [30] and is likely to play a role in
the aggressiveness of the AML-NS8 tumour.
After in vivo stabilisation, expanded AML-NS8 cells were
injected iv to induce disseminated disease which led to animal
death within 28–30 days. The tumour dissemination was analysed
in all haematopoietic and non haematopoietic organs using a
variety of techniques including immunohistochemistry, flow
cytometry and MRI. The data showed a clear infiltration of
neoplastic cells in BM, lung, soft tissues and meninges in about
90% of mice and presence of solid masses in 25% of cases. Besides,
small infiltrates of neoplastic cells were also present in spleen,
blood, kidney, and liver. The infiltration of AML-NS8 cells within
meninges of both column and skull and the documented presence
of tumoural masses always associated with bones suggested that
leukaemic cells in BM induced bone resorption, with consequent
invasion of meninges on one side and muscles on the other,
forming solid neoplasms.
Interestingly the overall distribution and localisation of
neoplastic cells in extramedullary compartment and formation of
solid masses as well as CNS and periodontal space involvement are
common characteristics observed in patients AML-M5 [31], even
if a direct correlation with the donor patient was not feasible due
to his early death. Besides, CD56, expressed in 15–20% AML
cases, is often associated with monocytic characteristics and with
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some chromosomal aberrations such as trisomy 8 [32]. It is also
correlated, together with 11q23 abnormalities, with extramedul-
lary and aggressive disease, CNS involvement, poor prognosis and
early death [7–9,11,32–35]. CD56 is a neuronal cell adhesion
molecule whose precise function and ligands are still unknown.
Thus whether and how CD56 expressed by tumour cells may
influence directly or indirectly the extramedullary localisation of
leukaemic cells is an important question that still needs to be
answered. There are indications that RUNX1 (AML1) isoforms
can regulate CD56 expression [36], however it is still unclear how
this may be linked to tumour aggressiveness. The AML-NS8
model described here may therefore be a useful tool to answer
some of these questions.
AML-NS8 cells did not show genetic alterations therapeutically
targetable so an alternative strategy could be represented by cell
cycle inhibitors. PLK are a family of ser/thr kinases composed of 5
members, most of which are involved in cell cycle control. PLK1,
that is the best studied of the family, phosphorylates cyclin B1,
activates the cyclin B/Cdk1 complex and cooperates with Aurora
kinases, thus controlling mitosis. It is also important for
centrosome maturation, cohesion of sister chromatids and exit
from mitosis [15,26]. PLK1 is an attractive target in cancer, since
it is overexpressed in a variety of solid tumours and in some
leukaemias, most prominently in. AML [13,37]. AML-NS8 cells
were found to express this kinase and to respond to our PLK1
inhibitor NMS-P937 in vitro at nanomolar doses leading to G2/M
arrest and increase of mitotic markers. A comparable activity was
previously observed in several other AML cell lines, irrespective of
FAB subtype [14]. Furthermore, in the in vivo disseminated AML-
NS8 model, this novel oral targeted drug significantly prolonged
survival compared to conventional therapies not only in the
preemptive protocol, in which the compound was administered
concomitantly with leukemic cells injection, but especially in the
therapeutic protocol where the treatment started 20 days after
tumour engraftment. With this schedule, better resembling the
clinical condition of patients in treatment, our PLK1 inhibitor
NMS-P937 had a stronger effect (MST=62 days) compared to
cytarabine (MST=36 days) and vehicle (MST=28 days) and
produced a better %T/C than in the preemptive protocol (221%
vs 175% respectively). Importantly in the therapeutic protocol, our
PLK1 inhibitor significantly decreased or abolished leukaemic
infiltration in meninges and soft tissues compared to cytarabine or
vehicle. These promising results, even if obtained only in one case
of aggressive AML, togheter with the efficacy of this inhibitor in
other AML models [14] add further support to the possibility of
targeting PLK1 in AML. Several PLK1 inhibitors have entered
clinical studies in solid cancers and hematopoietic malignancies
[14,26]. Indeed a Phase I/II trial is ongoing with BI6727 in
monotherapy or in combination with cytarabine in AML
(clinicalTrial.gov NCT 00804856).
An important aspect in the evaluation of targeted therapies is
the availability of reliable biomarkers to correlate the efficacy of a
new drug to its mechanism of action and afterwards to translate in
clinical practice. So, as suggested by Berg et al. [38], we put our
efforts to define biomarkers reflecting treatment response in our
model of AML. We could demonstrate inhibition of phosphory-
lation of pTCTP, a direct substrate of PLK1, and induction of
phosphorylation of the mitotic markers Histone H3 and NPM1,
other than increase of apoptosis, in meninges and extramedullary
masses from NMS-P937 treated mice. This is of particular interest
because it suggests that these molecular events are indeed the
in vivo mechanism of action of the drug and it indicates that the
AML-NS8 model is manageable for mechanistic studies. Finally,
we could also show the possibility of following extramedullary
infiltrations by MRI and this represents an additional tool for
studying drug efficacy.
In summary, we demonstrate that this new mouse model of
CD56+ AML provides a relevant system for integrating drug
screening with biomarker evaluation. The efficacy of our PLK1
inhibitor NMS-P937 in this model supports its clinical develop-
ment in leukaemias.
Supporting Information
Figure S1 Cytogenetic analysis of AML-NS8 samples. (A)
Bone marrow sample from patient at diagnosis. Cytogenetic
analysis (Q-banding) showed the presence of 2 clones, one with
trisomy 8 in 7 out of 22 metaphases (A1) and the other the double
trisomy of chromosome 6 and 8 in 15 out of 22 metaphases (A2).
(B) AML-NS8 cells expanded in mice. Cytogenetic analysis
showed the double trisomy of chromosome 6 and 8. (C) FISH
analysis. In vivo expanded cells cytocentrifuged and analyzed by
FISH, confirmed the same evidence observed in B. The
centromeres of chromosome 6 and chromosome 8 are stained in
red and green respectively.
(TIF)
Figure S2 Histopathological analysis and Magnetic
Resonance Imaging (MRI) of bone structures. SCID mice
were inoculated iv with 56106 AML-NS8 cells and sacrificed upon
manifestations of terminal disease. Column and skull were
collected and fixed for histological analysis by H&E staining.
The skull was also visualised by magnetic resonance imaging. (A)
column transversal section (H&E) at625 magnification. Massive
neoplastic cells infiltration of the muscle (ms), epidural space/
meninges (es/m) and vertebral bone marrow (BM) was evident
accompanied by areas of bone resorption (arrows). The neoplastic
cells are stained blue. Black bar, 1 mm. (B) skull transversal section
(H&E) at 610 magnification. Deep neoplastic infiltration of
epidural space/meninges (es/m). Arrow indicates macroscopic
mass growing on the skull surface. Black bar, 1 mm. (C) T2-
weighted MR image of the skull transversal section. A large area of
meningeal neoplastic infiltration (indicated in yellow) is visible and
surrounds the whole brain.
(TIF)
Figure S3 Biomarker expression in meninges of vehicle
or NMS-P937 treated animals. Skull from vehicle or NMS-
P937 treated animals were collected, fixed and paraffin embedded.
Serial sections were stained with H&E or antibodies against
phospho-TCTP (pTCTP), phospho-Histone H3 (pH3) or phos-
pho-NPM1 (pNPM1). Severe infiltration by leukaemic cells was
evident in the epidural space and meninges (es/m) under skull
bone (b). As already seen in tumor masses, and as aspected due to
its mechanism of action, NMS-P937 abolished the expression of its
direct substrate pTCTP and increased mitotic markers also in
meninges. Representative pictures at 6100 are reported. Inserts
show high magnification at6400. Black/white bar, 200 mm.
(TIF)
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